Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City. The company will engage in a Fireside Chat on Tuesday, May 20 at 10:30 AM EDT at NASDAQ. Additionally, TBPH will conduct in-person meetings with the investment community during the conference.
Investors can access the webcast through Theravance's website under the Investors section, Events and Presentations. The webcast recording will remain available for replay on the company's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la sua partecipazione alla 3陋 Conferenza Annuale BioConnect per Investitori di H.C. Wainwright a New York City. L'azienda prender脿 parte a una Fireside Chat il marted矛 20 maggio alle 10:30 AM EDT presso il NASDAQ. Inoltre, TBPH terr脿 incontri in presenza con la comunit脿 degli investitori durante la conferenza.
Gli investitori potranno seguire la diretta streaming sul sito web di Theravance, nella sezione Investitori, sotto Eventi e Presentazioni. La registrazione della diretta sar脿 disponibile per la visione on demand sul sito aziendale per 30 giorni dopo l'evento.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado su participaci贸n en la 3陋 Conferencia Anual BioConnect para Inversores de H.C. Wainwright en la ciudad de Nueva York. La compa帽铆a participar谩 en una Fireside Chat el martes 20 de mayo a las 10:30 AM EDT en NASDAQ. Adem谩s, TBPH realizar谩 reuniones presenciales con la comunidad inversora durante la conferencia.
Los inversores podr谩n acceder a la transmisi贸n en vivo a trav茅s del sitio web de Theravance, en la secci贸n de Inversores, Eventos y Presentaciones. La grabaci贸n estar谩 disponible para reproducci贸n durante 30 d铆as posteriores al evento.
Theravance Biopharma (NASDAQ: TBPH)臧� 雺挫殨鞁滌棎靹� 鞐措Μ電� H.C. Wainwright 鞝�3須� 鞐半 BioConnect 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 5鞗� 20鞚� 頇旍殧鞚� 鞓れ爠 10鞁� 30攵� EDT鞐� NASDAQ鞐愳劀 歆勴枆霅橂姅 Fireside Chat鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 霕愴暅, TBPH電� 旎嵓霟办姢 旮瓣皠 霃欖晥 韴瀽鞛愲摛瓿检潣 雽�氅� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚� Theravance 鞗轨偓鞚错姼鞚� 韴瀽鞛� 靹轨厴 雮� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴鞐愳劀 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟. 鞗轨簮鞀ろ姼 雲鬼檾電� 頄夓偓 膦呺 頉� 30鞚缄皠 須岇偓 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Theravance Biopharma (NASDAQ : TBPH) a annonc茅 sa participation 脿 la 3e conf茅rence annuelle BioConnect pour investisseurs de H.C. Wainwright 脿 New York. La soci茅t茅 participera 脿 une discussion informelle (Fireside Chat) le mardi 20 mai 脿 10h30 EDT au NASDAQ. De plus, TBPH tiendra des r茅unions en personne avec la communaut茅 des investisseurs durant la conf茅rence.
Les investisseurs pourront acc茅der au webdiffusion via le site internet de Theravance, dans la section Investisseurs, 脡v茅nements et Pr茅sentations. L鈥檈nregistrement restera disponible en replay sur le site de la soci茅t茅 pendant 30 jours apr猫s l鈥櫭﹙茅nement.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der 3. j盲hrlichen BioConnect Investorenkonferenz von H.C. Wainwright in New York City angek眉ndigt. Das Unternehmen wird am Dienstag, den 20. Mai um 10:30 Uhr EDT an einem Fireside Chat am NASDAQ teilnehmen. Zus盲tzlich wird TBPH w盲hrend der Konferenz pers枚nliche Treffen mit der Investoren-Community abhalten.
Investoren k枚nnen den Webcast 眉ber die Theravance-Website unter dem Bereich Investoren, Veranstaltungen und Pr盲sentationen verfolgen. Die Aufzeichnung des Webcasts wird f眉r 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verf眉gbar sein.
- None.
- None.
A webcast of the event may be accessed by visiting , under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference庐 in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI庐 (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit .
THERAVANCE BIOPHARMA庐, THERAVANCE庐 and the Cross/Star logo are registered trademarks of the聽Theravance Biopharma聽group of companies (in the聽U.S.聽and certain other countries).
YUPELRI庐聽is a registered trademark of聽Mylan Specialty L.P., a聽Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
View original content to download multimedia:
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the H.C. Wainwright BioConnect Conference?
Where can I watch Theravance Biopharma's (TBPH) H.C. Wainwright conference presentation?
What type of presentation will TBPH give at the H.C. Wainwright conference?
How long will TBPH's H.C. Wainwright conference webcast be available for replay?
